tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

PCRX Stock Latest News

Pacira BioSciences authorizes $300M share repurchase program
The FlyPacira BioSciences authorizes $300M share repurchase program
9d ago
PCRX
Pacira reports inducement grants under Nasdaq listing rule
PremiumThe Fly
Pacira reports inducement grants under Nasdaq listing rule
15d ago
PCRX
Pacira price target raised to $28 from $25 at Truist
PremiumThe Fly
Pacira price target raised to $28 from $25 at Truist
18d ago
PCRX
Positive Outlook for Pacira Pharmaceuticals Amid Exparel Settlement and Strategic Growth Initiatives
PremiumRatings
Positive Outlook for Pacira Pharmaceuticals Amid Exparel Settlement and Strategic Growth Initiatives
18d ago
PCRX
Pacira price target raised to $26 from $22 at RBC Capital
PremiumThe Fly
Pacira price target raised to $26 from $22 at RBC Capital
18d ago
PCRX
Pacira price target raised to $65 from $48 at H.C. Wainwright
PremiumThe FlyPacira price target raised to $65 from $48 at H.C. Wainwright
18d ago
PCRX
Closing Bell Movers: Levi Strauss up 8% on earnings, futures find footing
Premium
The Fly
Closing Bell Movers: Levi Strauss up 8% on earnings, futures find footing
19d ago
GBX
GME
Pacira Pharmaceuticals Settles Patent Litigation with Fresenius
Premium
Company Announcements
Pacira Pharmaceuticals Settles Patent Litigation with Fresenius
19d ago
8K
PCRX
Pacira announces settlement of U.S. patent litigation for Exparel
PremiumThe Fly
Pacira announces settlement of U.S. patent litigation for Exparel
19d ago
PCRX
Pacira announces first patient dosed in Phase 2 ASCEND study of PCRX-201
PremiumThe Fly
Pacira announces first patient dosed in Phase 2 ASCEND study of PCRX-201
23d ago
PCRX
Biotech stocks slide as Marks resignation seen being negative for sector
PremiumThe Fly
Biotech stocks slide as Marks resignation seen being negative for sector
26d ago
DYN
MGX
Marks resignation ‘not good’ for biotech sector, says RBC
PremiumThe Fly
Marks resignation ‘not good’ for biotech sector, says RBC
26d ago
DYN
RNA
DOMA Perpetual Capital nominates three director candidates to Pacira board
PremiumThe FlyDOMA Perpetual Capital nominates three director candidates to Pacira board
1M ago
PCRX
Pacira reports inducement grants under Nasdaq listing rule
Premium
The Fly
Pacira reports inducement grants under Nasdaq listing rule
2M ago
PCRX
PCRX Lawsuit Alert! Class Action Lawsuit Against Pacira Biosciences, Inc.
Premium
Market News
PCRX Lawsuit Alert! Class Action Lawsuit Against Pacira Biosciences, Inc.
2M ago
PCRX
Pacira BioSciences Reports Record Revenues and Strategic Growth
PremiumCompany Announcements
Pacira BioSciences Reports Record Revenues and Strategic Growth
2M ago
PCRX
Pacira price target raised to $24 from $17 at Barclays
PremiumThe Fly
Pacira price target raised to $24 from $17 at Barclays
2M ago
PCRX
Pacira price target raised to $22 from $18 at RBC Capital
PremiumThe Fly
Pacira price target raised to $22 from $18 at RBC Capital
2M ago
PCRX
Pacira Pharmaceuticals: Strategic Initiatives and Financial Outlook Drive Buy Rating
PremiumRatings
Pacira Pharmaceuticals: Strategic Initiatives and Financial Outlook Drive Buy Rating
2M ago
PCRX
Pacira Pharmaceuticals: Undervalued with Strong Growth Potential and Legal Protections Against Generic Competition
PremiumRatingsPacira Pharmaceuticals: Undervalued with Strong Growth Potential and Legal Protections Against Generic Competition
2M ago
PCRX
Pacira price target raised to $48 from $39 at H.C. Wainwright
Premium
The Fly
Pacira price target raised to $48 from $39 at H.C. Wainwright
2M ago
PCRX
Pacira BioSciences Reports Record Revenue Amid Strategic Growth
Premium
Company Announcements
Pacira BioSciences Reports Record Revenue Amid Strategic Growth
2M ago
PCRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >